Syncom Formulations
13.07
+0.05(+0.38%)
Market Cap₹1,228.58 Cr
PE Ratio19.46
IndustryHealthcare
Company Performance:
1D+0.38%
1M-12.40%
6M-30.48%
1Y-24.23%
5Y+61.36%
View Company Insightsright
More news about Syncom Formulations
20May 25
Syncom Formulations Reports Impressive Q4 Results with Soaring Profits and Revenue
Syncom Formulations announced impressive Q4 financial results. Net profit soared 159.26% year-over-year to ₹175.00 crore, up 36.72% quarter-over-quarter. Revenue reached ₹1,500.00 crore, a 104.72% increase from the previous year. The company's strong performance indicates effective business strategies and high market demand for its products.
19May 25
Syncom Formulations Reports Impressive Q4 Financial Results with Substantial Growth
Syncom Formulations announced impressive Q4 financial results, with revenue soaring 104% year-over-year to ₹1,500.00 crore. Net profit surged 159% to ₹175.00 crore, while EBITDA nearly doubled to ₹175.00 crore. Despite strong overall performance, EBITDA margin slightly decreased to 11.67% from 12.02% in the previous year.
Syncom Formulations
13.07
+0.05
(+0.38%)
1 Year Returns:-24.23%
Industry Peers
Sun Pharmaceutical
1,698.80
(-1.73%)
Divis Laboratories
6,389.00
(-0.74%)
Torrent Pharmaceuticals
3,953.50
(+0.33%)
Cipla
1,430.40
(-1.24%)
Lupin
2,199.30
(+0.93%)
Dr Reddys Laboratories
1,183.40
(-0.66%)
Mankind Pharma
2,238.40
(+1.11%)
Zydus Life Science
888.25
(-1.38%)
Alkem Laboratories
5,819.50
(-0.75%)
Aurobindo Pharma
1,186.10
(+1.58%)